Fig. 4

In vivo treatment with Angptl4 increases immature megakaryocytes and results in elevated platelet counts. a Hematoxylin-eosin staining of BM sections from PBS- or Angptl4-treated WT mice. Mice were daily injected with 250 μg/kg murine Angptl4 per kg body weight for five consecutive days and analyzed 48 h after the last injection. The symbol “x” indicates MKs in the BM of PBS- and rmAngptl-treated mice, and arrows indicate immature MKs in the BM of Angptl4-injected animals. One representative analysis from three independent experiments is shown. Magnification ×200. b Representative FACS profile of Lin⁻ BM cells from PBS- and Angptl4-injected WT mice. Lin⁻CD45⁺CD61⁺ cells were subdivided into three subsets based on CD61 and CD41 expression: CD61⁺, CD61⁺CD41^high, and CD61⁺CD41^low cells. c Frequency and total cell numbers/tibia of CD61⁺, CD61⁺CD41^high, and CD61⁺CD41^low cells. Mean ± SEM of three different experiments with three PBS-injected and three Angptl4-injected mice/group are shown. d PLT counts from PBS- or Angptl4-treated WT mice. Mean ± SEM of three different experiments with three PBS-injected and three Angptl4-injected mice/group are shown. Statistically significant differences are indicated (**p < 0.01)